Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma

Jiangbing Zhou, Toral R. Patel, Rachael W. Sirianni, Garth Strohbehn, Ming Qiang Zheng, Nha Duong, Thomas Schafbauer, Anita J. Huttner, Yiyun Huang, Richard E. Carson, Ying Zhang, David J. Sullivan, Joseph M. Piepmeier, W. Mark Saltzman

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

Current therapy for glioblastoma multiforme is insufficient, with nearly universal recurrence. Available drug therapies are unsuccessful because they fail to penetrate through the region of the brain containing tumor cells and they fail to kill the cells most responsible for tumor development and therapy resistance, brain cancer stem cells (BCSCs). To address these challenges, we combined two major advances in technology: (i) brain-penetrating polymeric nanoparticles that can be loaded with drugs and are optimized for intracranial convection-enhanced delivery and (ii) repurposed compounds, previously used in Food and Drug Administration- approved products, which were identified through library screening to target BCSCs. Using fluorescence imaging and positron emission tomography, we demonstrate that brain-penetrating nanoparticles can be delivered to large intracranial volumes in both rats and pigs. We identified several agents (from Food and Drug Administration-Approved products) that potently inhibit proliferation and self-renewal of BCSCs. When loaded into brain-penetrating nanoparticles and administered by convection-enhanced delivery, one of these agents, dithiazanine iodide, significantly increased survival in rats bearing BCSC-derived xenografts. This unique approach to controlled delivery in the brain should have a significant impact on treatment of glioblastoma multiforme and suggests previously undescribed routes for drug and gene delivery to treat other diseases of the central nervous system.

Original languageEnglish (US)
Pages (from-to)11751-11756
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume110
Issue number29
DOIs
StatePublished - Jul 16 2013

Fingerprint

Glioblastoma
Brain Neoplasms
Neoplastic Stem Cells
Brain Stem
Nanoparticles
Convection
Pharmaceutical Preparations
Brain
United States Food and Drug Administration
Dithiazanine
Therapeutics
Optical Imaging
Central Nervous System Diseases
Heterografts
Positron-Emission Tomography
Swine
Technology
Recurrence
Drug Therapy
Genes

ASJC Scopus subject areas

  • General

Cite this

Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma. / Zhou, Jiangbing; Patel, Toral R.; Sirianni, Rachael W.; Strohbehn, Garth; Zheng, Ming Qiang; Duong, Nha; Schafbauer, Thomas; Huttner, Anita J.; Huang, Yiyun; Carson, Richard E.; Zhang, Ying; Sullivan, David J.; Piepmeier, Joseph M.; Saltzman, W. Mark.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 110, No. 29, 16.07.2013, p. 11751-11756.

Research output: Contribution to journalArticle

Zhou, J, Patel, TR, Sirianni, RW, Strohbehn, G, Zheng, MQ, Duong, N, Schafbauer, T, Huttner, AJ, Huang, Y, Carson, RE, Zhang, Y, Sullivan, DJ, Piepmeier, JM & Saltzman, WM 2013, 'Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma', Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 29, pp. 11751-11756. https://doi.org/10.1073/pnas.1304504110
Zhou, Jiangbing ; Patel, Toral R. ; Sirianni, Rachael W. ; Strohbehn, Garth ; Zheng, Ming Qiang ; Duong, Nha ; Schafbauer, Thomas ; Huttner, Anita J. ; Huang, Yiyun ; Carson, Richard E. ; Zhang, Ying ; Sullivan, David J. ; Piepmeier, Joseph M. ; Saltzman, W. Mark. / Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma. In: Proceedings of the National Academy of Sciences of the United States of America. 2013 ; Vol. 110, No. 29. pp. 11751-11756.
@article{5e8ed2a014b84bfda2f3e92d727bfccd,
title = "Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma",
abstract = "Current therapy for glioblastoma multiforme is insufficient, with nearly universal recurrence. Available drug therapies are unsuccessful because they fail to penetrate through the region of the brain containing tumor cells and they fail to kill the cells most responsible for tumor development and therapy resistance, brain cancer stem cells (BCSCs). To address these challenges, we combined two major advances in technology: (i) brain-penetrating polymeric nanoparticles that can be loaded with drugs and are optimized for intracranial convection-enhanced delivery and (ii) repurposed compounds, previously used in Food and Drug Administration- approved products, which were identified through library screening to target BCSCs. Using fluorescence imaging and positron emission tomography, we demonstrate that brain-penetrating nanoparticles can be delivered to large intracranial volumes in both rats and pigs. We identified several agents (from Food and Drug Administration-Approved products) that potently inhibit proliferation and self-renewal of BCSCs. When loaded into brain-penetrating nanoparticles and administered by convection-enhanced delivery, one of these agents, dithiazanine iodide, significantly increased survival in rats bearing BCSC-derived xenografts. This unique approach to controlled delivery in the brain should have a significant impact on treatment of glioblastoma multiforme and suggests previously undescribed routes for drug and gene delivery to treat other diseases of the central nervous system.",
author = "Jiangbing Zhou and Patel, {Toral R.} and Sirianni, {Rachael W.} and Garth Strohbehn and Zheng, {Ming Qiang} and Nha Duong and Thomas Schafbauer and Huttner, {Anita J.} and Yiyun Huang and Carson, {Richard E.} and Ying Zhang and Sullivan, {David J.} and Piepmeier, {Joseph M.} and Saltzman, {W. Mark}",
year = "2013",
month = "7",
day = "16",
doi = "10.1073/pnas.1304504110",
language = "English (US)",
volume = "110",
pages = "11751--11756",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "29",

}

TY - JOUR

T1 - Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma

AU - Zhou, Jiangbing

AU - Patel, Toral R.

AU - Sirianni, Rachael W.

AU - Strohbehn, Garth

AU - Zheng, Ming Qiang

AU - Duong, Nha

AU - Schafbauer, Thomas

AU - Huttner, Anita J.

AU - Huang, Yiyun

AU - Carson, Richard E.

AU - Zhang, Ying

AU - Sullivan, David J.

AU - Piepmeier, Joseph M.

AU - Saltzman, W. Mark

PY - 2013/7/16

Y1 - 2013/7/16

N2 - Current therapy for glioblastoma multiforme is insufficient, with nearly universal recurrence. Available drug therapies are unsuccessful because they fail to penetrate through the region of the brain containing tumor cells and they fail to kill the cells most responsible for tumor development and therapy resistance, brain cancer stem cells (BCSCs). To address these challenges, we combined two major advances in technology: (i) brain-penetrating polymeric nanoparticles that can be loaded with drugs and are optimized for intracranial convection-enhanced delivery and (ii) repurposed compounds, previously used in Food and Drug Administration- approved products, which were identified through library screening to target BCSCs. Using fluorescence imaging and positron emission tomography, we demonstrate that brain-penetrating nanoparticles can be delivered to large intracranial volumes in both rats and pigs. We identified several agents (from Food and Drug Administration-Approved products) that potently inhibit proliferation and self-renewal of BCSCs. When loaded into brain-penetrating nanoparticles and administered by convection-enhanced delivery, one of these agents, dithiazanine iodide, significantly increased survival in rats bearing BCSC-derived xenografts. This unique approach to controlled delivery in the brain should have a significant impact on treatment of glioblastoma multiforme and suggests previously undescribed routes for drug and gene delivery to treat other diseases of the central nervous system.

AB - Current therapy for glioblastoma multiforme is insufficient, with nearly universal recurrence. Available drug therapies are unsuccessful because they fail to penetrate through the region of the brain containing tumor cells and they fail to kill the cells most responsible for tumor development and therapy resistance, brain cancer stem cells (BCSCs). To address these challenges, we combined two major advances in technology: (i) brain-penetrating polymeric nanoparticles that can be loaded with drugs and are optimized for intracranial convection-enhanced delivery and (ii) repurposed compounds, previously used in Food and Drug Administration- approved products, which were identified through library screening to target BCSCs. Using fluorescence imaging and positron emission tomography, we demonstrate that brain-penetrating nanoparticles can be delivered to large intracranial volumes in both rats and pigs. We identified several agents (from Food and Drug Administration-Approved products) that potently inhibit proliferation and self-renewal of BCSCs. When loaded into brain-penetrating nanoparticles and administered by convection-enhanced delivery, one of these agents, dithiazanine iodide, significantly increased survival in rats bearing BCSC-derived xenografts. This unique approach to controlled delivery in the brain should have a significant impact on treatment of glioblastoma multiforme and suggests previously undescribed routes for drug and gene delivery to treat other diseases of the central nervous system.

UR - http://www.scopus.com/inward/record.url?scp=84880347703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880347703&partnerID=8YFLogxK

U2 - 10.1073/pnas.1304504110

DO - 10.1073/pnas.1304504110

M3 - Article

VL - 110

SP - 11751

EP - 11756

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 29

ER -